Cronos Group Partners with Geocann to Leverage VESIsorb® Delivery Technology for Faster Absorption

3 min readPublished On: June 27th, 2022By

TORONTO – Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON), announce the launch of the first of what is expected to be a range of products, in partnership with Geocann, which will utilize the advanced VESIsorb® delivery system. This technology provides better bioavailability and faster absorption. VESIsorb® formulations have set the industry benchmark in peer-reviewed published studies, delivering superior pharmacokinetic performance, including fast absorption, higher plasma concentration, and greater area under the curve.

“We are committed to bringing breakthrough innovations to the market, providing consumers with differentiated and high-quality products,” said Mike Gorenstein, Chairman, President and Chief Executive Officer, Cronos. “Working with Geocann’s technology enables us to expand our product offering to bring consumers a fast-acting cannabinoid product with a quicker onset than previously available, along with improved efficacy, helping enhance and differentiate effect and experience.”

VESIsorb® is the delivery system innovation for improving the bioavailability of difficult-to-absorb ingredients, like cannabinoids and terpenes. This patented technology has been shown to have faster absorption in both well-designed pilot and peer-reviewed published studies. Geocann is the exclusive supplier of the VESIsorb® delivery system for cannabinoids, terpenes, and flavonoid formulations, and is well-recognized for its substantial investments in research and product development in order to meet the needs of the marketplace.

“As leading companies in our respective sectors, Geocann and Cronos are uniquely positioned to set new industry benchmarks for the performance of cannabinoid products,” Jesse Lopez, Chief Executive Officer and founder of Geocann, said. “Most importantly, Geocann is proud to support the innovative brands under the Cronos umbrella.”

The first VESIsorb® formulated product the companies have launched together are the CBD Gel Capsules by Lord Jones®. The companies look forward to collaborating in the future on innovative products and formulations.

Forward-looking Statements of Cronos Group Inc.
This press release may contain information that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws (collectively, “Forward-looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include the companies’ launch of a range of products and future collaboration on innovative products and formulations and Cronos’ intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the period ended March 31, 2022, both have which been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos Group disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

(This information is primarily sourced from Cronos Group Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!